Here you will find the recommendations we have made about the use of individual medicines in Lancashire.


Brand: Praluent®
NICE TA: 393
Indication: Treating primary hypercholesterolaemia and mixed dyslipidaemia (NICE TA393)
Disease category: Cardiovascular system
Commissioning responsibility: CCG
PbR excluded: Yes


Alirocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
• Low-density lipoprotein concentrations are persistently above the thresholds specified in table 1 (see NICE TA 393) despite maximal tolerated lipid-lowering therapy. That is, either the maximum dose has been reached or further titration is limited by intolerance (as defined in NICE’s guideline on familial hypercholesterolaemia: identification and management).
• The company provides alirocumab with the discount agreed in the patient access scheme.

This guidance is not intended to affect the position of patients whose treatment with alirocumab was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.


LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision:  Specialist medicine

Supporting documents:

NICE TA393 - Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG